TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.
- DOI
- 10.1080/14796694.2026.2702768
- Published
- 2026 Aug
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2026.2702768,
title = {TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.},
author = {Gelderblom H and Palmerini E and van de Sande M and Martin-Broto J and Tinoco G and Seltzer E and Davies M and Coll R and Veltkamp S and Blay JY},
year = {2026},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2026.2702768},
url = {https://doi.org/10.1080/14796694.2026.2702768}
}RIS
TY - JOUR TI - TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. AU - Gelderblom H AU - Palmerini E AU - van de Sande M AU - Martin-Broto J AU - Tinoco G AU - Seltzer E AU - Davies M AU - Coll R AU - Veltkamp S AU - Blay JY PY - 2026 JO - Future oncology (London, England) DO - 10.1080/14796694.2026.2702768 UR - https://doi.org/10.1080/14796694.2026.2702768 ER -
APA
H, G., E, P., M, V. D. S., J, M., G, T., E, S., M, D., R, C., S, V., & JY, B. (2026). TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2702768
Source records
- pubmed · retrieved 2026-09-26T05:51:41.195Z